Microbleeds are associated with depressive symptoms in Alzheimer's disease

by Anna E. Leeuwis, Niels D. Prins, Astrid M. Hooghiemstra, Marije R. Benedictus, Philip Scheltens, Frederik Barkhof, Wiesje M. van derFlier
Published 2018-01-01

The “rights” of precision drug development for Alzheimer’s disease

by Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
Published 2019-08-01

Blood‐based metabolic signatures in Alzheimer's disease

by Francisca A. deLeeuw, Carel F.W. Peeters, Maartje I. Kester, Amy C. Harms, Eduard A. Struys, Thomas Hankemeier, Herman W.T. vanVlijmen, Sven J. van derLee, Cornelia M. vanDuijn, Philip Scheltens, Ayşe Demirkan, Mark A. van deWiel, Wiesje M. van derFlier, Charlotte E. Teunissen
Published 2017-01-01

Reproducibility of EEG functional connectivity in Alzheimer’s disease

by Casper T. Briels, Deborah N. Schoonhoven, Cornelis J. Stam, Hanneke de Waal, Philip Scheltens, Alida A. Gouw
Published 2020-06-01

Heterogeneity of Alzheimer’s disease: consequence for drug trials?

by Gayatri Devi, Philip Scheltens
Published 2018-12-01

Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

by Mara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N. M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, Derek Hill, Michael C. Irizarry, Adriaan A. Lammertsma, José Luis Molinuevo, Craig Ritchie, Philip Scheltens, Mark E. Schmidt, Pieter Jelle Visser, Adam Waldman, Joanna Wardlaw, Sven Haller, Frederik Barkhof
Published 2018-10-01

On the path to 2025: understanding the Alzheimer’s disease continuum

by Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens, Bruno Dubois
Published 2017-08-01

Single-subject grey matter graphs in Alzheimer's disease.

by Betty M Tijms, Christiane Möller, Hugo Vrenken, Alle Meije Wink, Willem de Haan, Wiesje M van der Flier, Cornelis J Stam, Philip Scheltens, Frederik Barkhof
Published 2013-01-01

Exercise and Early-Onset Alzheimer’s Disease: Theoretical Considerations

by Astrid M. Hooghiemstra, Laura H.P. Eggermont, Philip Scheltens, Wiesje M. van der Flier, Erik J.A. Scherder
Published 2012-04-01

Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease

by Baayla D. C. Boon, Jeroen J. M. Hoozemans, Boaz Lopuhaä, Kristel N. Eigenhuis, Philip Scheltens, Wouter Kamphorst, Annemieke J. M. Rozemuller, Femke H. Bouwman
Published 2018-05-01

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease

by Nienke M.E. Scheltens, Kars van der Weijden, Sofie M. Adriaanse, Danielle van Assema, Priscilla P. Oomen, Welmoed A. Krudop, Adriaan A. Lammertsma, Frederik Barkhof, Teddy Koene, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, Maqsood Yaqub, Rik Ossenkoppele, Bart N.M. van Berckel
Published 2018-01-01

The predictive value of normal EEGs in dementia due to Alzheimer’s disease

by Casper T. Briels, Cornelis J. Stam, Philip Scheltens, Alida A. Gouw
Published 2021-05-01

Correction: Single-Subject Grey Matter Graphs in Alzheimer's Disease

by Betty M. Tijms, Christiane Möller, Hugo Vrenken, Alle Meije Wink, Willem de Haan, Wiesje M. van der Flier, Cornelis J. Stam, Philip Scheltens, Frederik Barkhof
Published 2013-01-01

Activity dependent degeneration explains hub vulnerability in Alzheimer's disease.

by Willem de Haan, Katherine Mott, Elisabeth C W van Straaten, Philip Scheltens, Cornelis J Stam
Published 2012-01-01

Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease

by Ellen H. Singleton, Yolande A. L. Pijnenburg, Carole H. Sudre, Colin Groot, Elena Kochova, Frederik Barkhof, Renaud La Joie, Howard J. Rosen, William W. Seeley, Bruce Miller, M. Jorge Cardoso, Janne Papma, Philip Scheltens, Gil D. Rabinovici, Rik Ossenkoppele
Published 2020-11-01

Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?

by Jurre denHaan, Jacoba A. van deKreeke, Bart N. vanBerckel, Frederik Barkhof, Charlotte E. Teunissen, Philip Scheltens, Frank D. Verbraak, Femke H. Bouwman
Published 2019-12-01

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease

by Rosha Babapour Mofrad, Niki S.M. Schoonenboom, Betty M. Tijms, Philip Scheltens, Pieter Jelle Visser, Wiesje M. van derFlier, Charlotte E. Teunissen
Published 2019-12-01

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.

by Stephanie J B Vos, Pieter Jelle Visser, Frans Verhey, Pauline Aalten, Dirk Knol, Inez Ramakers, Philip Scheltens, Marcel G M Olde Rikkert, Marcel M Verbeek, Charlotte E Teunissen
Published 2014-01-01

Correction: Single-Subject Grey Matter Graphs in Alzheimer's Disease.

by Betty M. Tijms, Christiane Möller, Hugo Vrenken, Alle Meije Wink, Willem de Haan, Wiesje M. van der Flier, Cornelis J. Stam, Philip Scheltens, Frederik Barkhof
Published 2013-01-01

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals

by Betty M. Tijms, Lisa Vermunt, Marissa D. Zwan, Argonde C. vanHarten, Wiesje M. van derFlier, Charlotte E. Teunissen, Philip Scheltens, Pieter Jelle Visser, for ADNI
Published 2018-09-01